AmerisourceBergen (ABC) Tops Q2 EPS by 9c, Sales Miss; FY EPS Raised

AmerisourceBergen (NYSE: ABC) reported Q2 EPS of $1.77, $0.09 better than the analyst estimate of $1.68. Revenue for the quarter came in at $37.1 billion versus the consensus estimate of $38.09 billion.

GUIDANCE:

AmerisourceBergen sees FY2017 EPS of $5.77-$5.92, versus the consensus of $5.82.

“AmerisourceBergen is consistently delivering solid performance in a challenging marketplace. We are very pleased with our second quarter results, our team’s ability to strategically execute and the continued growth of our anchor customers. We also take great pride in our strong customer relationships, including our long-term contract with Express Scripts, which we recently renewed and now extends through 2022,” said Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen. “We offer our pharmaceutical manufacturer and provider customers the most innovative and business-critical services and solutions to support and drive their growth. The overall response to these offerings has been extremely positive and their adoption continues to grow.”

“In the second quarter of the fiscal year, we continued to lead the market in specialty distribution and pharmaceutical services, deliver excellent growth across our businesses in Other - including Consulting Services, MWI Animal Health and World Courier - and effectively manage our operating expenses,” Mr. Collis continued. “As we move further into 2017, we continue to have great confidence in our unique portfolio of integrated services, the significant value we bring to our customers and our ability to create healthier futures - AmerisourceBergen enables people to access the healthcare products they need, ultimately improving the lives of patients and delivering long-term value to all of our stakeholders.”

For earnings history and earnings-related data on AmerisourceBergen (ABC) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Cineverse Corp (CNVS) Misses Q1 EPS by 20c; Offers Guidance
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c